UroGen Pharma Stock Forecast, Price & News

-1.43 (-7.45 %)
(As of 04/12/2021 03:33 PM ET)
Today's Range
Now: $17.77
50-Day Range
MA: $20.10
52-Week Range
Now: $17.77
Volume6,552 shs
Average Volume206,263 shs
Market Capitalization$371.34 million
P/E RatioN/A
Dividend YieldN/A
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.
UroGen Pharma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:URGN
Year FoundedN/A



Sales & Book Value

Annual Sales$20,000.00
Price / Sales18,566.98
Book Value$8.63 per share


Net Income$-105,150,000.00


Market Cap$371.34 million
Next Earnings Date5/6/2021 (Estimated)


UroGen Pharma: Q4 Earnings Insights
March 18, 2021 |
UroGen Pharma Announces March 2021 Conference Schedule
February 23, 2021 |
UroGen Pharma Ltd. (NASDAQ:URGN): Are Analysts Optimistic?
January 26, 2021 |
See More Headlines


Overall MarketRank

1.76 out of 5 stars

Medical Sector

183rd out of 2,011 stocks

Pharmaceutical Preparations Industry

78th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-1.43 (-7.45 %)
(As of 04/12/2021 03:33 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

UroGen Pharma (NASDAQ:URGN) Frequently Asked Questions

Is UroGen Pharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UroGen Pharma stock.
View analyst ratings for UroGen Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than UroGen Pharma?

Wall Street analysts have given UroGen Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but UroGen Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is UroGen Pharma's next earnings date?

UroGen Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for UroGen Pharma

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) announced its earnings results on Wednesday, March, 17th. The company reported ($1.38) EPS for the quarter, missing the Zacks' consensus estimate of ($1.37) by $0.01.
View UroGen Pharma's earnings history

How has UroGen Pharma's stock been impacted by COVID-19 (Coronavirus)?

UroGen Pharma's stock was trading at $23.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, URGN shares have decreased by 23.9% and is now trading at $18.15.
View which stocks have been most impacted by COVID-19

What price target have analysts set for URGN?

3 brokerages have issued twelve-month price targets for UroGen Pharma's shares. Their forecasts range from $26.00 to $57.00. On average, they expect UroGen Pharma's share price to reach $42.25 in the next year. This suggests a possible upside of 132.8% from the stock's current price.
View analysts' price targets for UroGen Pharma
or view top-rated stocks among Wall Street analysts.

Who are UroGen Pharma's key executives?

UroGen Pharma's management team includes the following people:
  • Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 59, Pay $1.84M)
  • Dr. Mark P. Schoenberg, Chief Medical Officer (Age 63, Pay $476.6k)
  • Mr. Ron Bentsur, Advisor (Age 55, Pay $699.77k)
  • Ms. Molly Henderson CPA, MBA, Chief Financial Officer (Age 50)
  • Sara Blum Sherman, Sr. Director of Investor Relations
  • Mr. Jason Smith, Gen. Counsel & Chief Compliance Officer
  • Eric Van Zanten, Sr. Director of Communications
  • Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director
  • Dr. Marina Konorty, Exec. VP of R&D and Technical Operations
  • Mr. Jeffrey Bova M.B.A., Chief Commercial Officer

Who are some of UroGen Pharma's key competitors?

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu Biopharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How do I buy shares of UroGen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $18.15.

How much money does UroGen Pharma make?

UroGen Pharma has a market capitalization of $379.28 million and generates $20,000.00 in revenue each year. The company earns $-105,150,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis.

How many employees does UroGen Pharma have?

UroGen Pharma employs 187 workers across the globe.

What is UroGen Pharma's official website?

The official website for UroGen Pharma is

Where are UroGen Pharma's headquarters?

UroGen Pharma is headquartered at 400 Alexander Park, Princeton NJ, 08540.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at 646-768-9780 or via email at [email protected]

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.